

INTRODUCTION

Sepsis

Systemic inflammatory event triggered by pathogen or damage-associated activation of the toll-like receptor (TLR) system

Mechanisms of TLR Activation

- <u>Classic Sepsis</u>: Infection via lipopolysaccharide (LPS) and lipoteichoic acid (Gram positive).
- Sterile Sepsis: Poly-trauma and ischemia from DNA, histones and other components of necrotic cells

Stages and Symptoms

- Mild Sepsis: Temperature, tachycardia, hyperventilation
- Endothelial Dysfunction blood vessel leakiness
- Severe Sepsis: Hypotension, organ hypoperfusion, altered mental state
- Septic Shock: Hypotension, hypoperfusion, elevated lactate. 50% mortality.

Curcumin

Primary curcuminoid found in turmeric root. Long implicated as a potent anti-inflammatory agent.

Anti-inflammatory Mechanisms

- Downregulation of TLR-4
- Blockade of NF-кВ
- Increases endothelial nitric oxide production to improve vascular function
- May alter epigenetic modifier (DNMT-1, SIRT1, etc) expression

Therapeutic Challenges

- Poor solubility in water
- Difficult to reach bioactive potency

VASCEPTOR™

Transdermal platform that facilitates systemic delivery of curcuminoids

- Applied topically as a cream
- High concentration of curcuminoids
- Rapid delivery and prolonged anti-hypertensive action

METHODS & MATERIALS

Endotoxemic Modelling of Sepsis

• Daily (every 24h) IP injections of LPS (Sigma Aldrich, St. Louis, MO; 10 mg/kg) for 72h

Treatment

- Anesthetized with Isoflurane
- LPS administered
- Back shaved and cleaned
- 0.1 mL of topical agent applied
- Tegaderm affixed over agent
- Treatments concurrent with LPS (Once every 24h for 72h)





CUR

- Groups • <u>LPS+VC</u> (Vehicle Control; LPS+0.1 mL topical agent without curcumin; N = 7)
- <u>LPS+CUR</u> (VASCEPTOR; LPS+0.1 mL topical agent with curcumin; N = 7)
- <u>No LPS</u> (Healthy Control; no LPS, no topical agent; N = 8)


Extravasation Protocol

- At 72h: animals anesthetized and surgically cannulated for cardiovascular monitoring, blood sampling, and fluorescence microscopy of the exteriorized spinotrapezius muscle.
- 67 kDa TRITC bovine serum albumin admin administered after baseline parameters
- Fluorescence was measured in the interstitial fluid of the spinotrapezius for 30 minutes
- Phenylephrine was administered at the end of the study to measure arteriolar responsiveness

Novel Transdermal Curcumin Therapeutic Preserves Endothelial Barrier Function in a Rat Model of Sepsis.

William H. Nugent PhD¹, Pedro Cabrales PhD², Danuel A. Carr BSc¹, Probal Banerjee PhD³, Joel Friedman^{4,5} and Bjorn K. Song PhD^{1,5}

FLOURESCENT 67 KDA ALBUMIN EXTRAVASATION











Figure 1: Accumulation of Fluorescent Albumin in the Spinotrapezius

Images (5X magnification) were captured by a monochromatic digital camera using identical flash intensity and exposure times for each series. Contrast and brightness were adjusted for presentation using the Zen II software and standardized for all images.

CARDIOVASCULAR




72h Heart Rate

500· 450· LPS+VCLPS+CUR No LPS

Figure 4: Physiological profile of LPS regimen.

Lactate, an indicator of hypoperfusion, was elevated for Vehicle after 24 h of treatment. LPS+CUR animals trended lower than LPS+VC but higher than No LPS. Heart Rate and Mean Arterial Pressure were assessed at 72h before extravasation experiments. Heart Rate trended higher for Vehicle, with tachycardia consistent expected in sepsis. Mean Arterial Pressure was low for both LPS-treated groups, but lowest for LPS+CUR. Data are mean ± SEM.

72h Mean Arterial Pressure



* p < 0.05 vs LPS+VC


LPS+CUI 1.6 -Minutes

Figure 2: Albumin Extravasation

TRITC bovine serum albumin was injected IV and monitored with fluorescence microscopy of the spinotrapezius microvasculature. Accumulation in the interstitial fluid was measured as intensity, normalized to BL, and expressed as fold change. Exposure times varied slightly between experiments (1500-2000 ms) to account for differing tissue thicknesses but were not changed within each time course. Data are mean ± SEM.

* p < 0.05 vs LPS+VC

INFLAMMATORY MARKERS






Figure 5: Protein expression of cytokine IL-6 and neutrophil chemokine CXCL5 (LIX)

Plasma samples were quantified with ELISA. Values for both CXCL5 and IL6 proteins (pg/ml) normalized to were baseline (before initial LPS treatment) at 0 h for a comparison of relative change within groups. For CXCL5, differences between LPS+VC and LPS+CUR were trending at 72 h (p = 0.14), but not resolved at N values of 7. The Y-axis for IL6 was set to Log10 and a significant rise was seen for LPS+VC compared to 0h. For LPS+VC vs. LPS+CUR, p=0.25. Data are mean \pm SEM.

 $\beta p < 0.05$ versus 0 h | ** p < 0.01 versus No LPS

CXCL5



VASCULAR RESPONSE TO PE

Arteriolar Lumenal Diameter




Figure 3: Arteriolar Response to Phenylephrine

Pressers are used to relieve hypotension in sepsis through peripheral vasoconstriction. Since they inevitably lead to distal ischemia, co-treatments that can limit their use are desirable. After 72 h of endotoxemia and the extravasation test, a site containing second order arterioles 100-30 µm was selected and imaged. 0.1 M PE was infused, and maximal vessel contraction measured. Data are mean ± SEM.

* p < 0.05 vs No LPS and LPS+VC

CONCLUSIONS

Curcumin:

- Lowered cardiovascular burden of endotoxemia
- Prevented LPS-induced extravasation
- Reduced inflammatory markers Increased vascular responsiveness to PE

Hypotension was noted for LPS+CUR, but may be a contaminant effect of enhanced NO production rather than an indicator of illness

Results suggest efficacy of VASCEPTOR in mitigating inflammatory dysregulated disorders and enhancing effectiveness of pressor treatments.

INSTITUTIONS

- 1. Song Biotechnologies LLC, Cockeysville, MD
- 2. Dept. of Bioengineering, University of California, San Diego, CA 3. Dept. of Chemistry, City University of New York, Staten Island, NY
- 4. Dept. of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY
- 5. Vascarta, Inc, Summit, NJ